Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Phase 3

Completed

• Conditions: Chronic Strongyloidiasis
• Interventions: Drug: ivermectin; Drug: Albendazole

• Registration Number: NCT00765024
• Lead Sponsor: Mahidol University

Brief Summary

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2008-09-30
• Study First Submitted QC: 2008-09-30
• Study First Posted: 2008-10-02
• Primary Completion: 2010-04
• Study Completion: 2010-04
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-03
• Last Update Posted: 2017-09-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• Patients with positive strongyloides larva in the stool

Exclusion Criteria

• Pregnancy
• Lactating women
• Known allergy to any study drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ivermectin 2 doses	ivermectin	ivermectin 200 mcg/kg two doses in 2 weeks
Albendazole	Albendazole	Albendazole for 7 days
ivermectin	ivermectin	ivermectin 200 mcg/kg single dose

Primary Outcome Measures

Name	Time	Method
cure rate	1 year

Secondary Outcome Measures

Name	Time	Method
safety	1 year

Trial Locations

Locations (1)

Siriraj Hospital; 🇹🇭 Bangkoknoi, Bangkok, Thailand